Black Swan Sale

50% Off Elite

Get our most powerful screeners, new charting tools, and the fastest ad-
free experience at our best price ever. This deal may never happen again.

SPRO

Spero Therapeutics Inc

Nov 28 • 02:24PM ET

2.40

+0.07 3.00 %

Healthcare • Biotechnology • USA • NASD

Peers: AVIR CDTX AMRX TVRD ANIP CBIO DSGN FENC CSBR HURA

| Held by: VTI VXF QQQS DFAS DFAC

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-0.79	Insider Own	27.41%	Shs Outstand	56.31M	Perf Week	6.19%
Market Cap	135.21M	Forward P/E	-	EPS next Y	-0.64	Insider Trans	-0.31%	Shs Float	40.90M	Perf Month	3.00%
Enterprise Value	89.94M	PEG	-	EPS next Q	-0.20	Inst Own	14.62%	Short Float	1.51%	Perf Quarter	15.94%
Income	-43.84M	P/S	4.61	EPS this Y	48.82%	Inst Trans	0.45%	Short Ratio	0.97	Perf Half Y	-4.00%
Sales	29.32M	P/B	5.10	EPS next Y	1.54%	ROA	-46.31%	Short Interest	0.62M	Perf YTD	133.01%
Book/sh	0.47	P/C	2.78	EPS next 5Y	18.80%	ROE	-95.29%	52W High	3.22 -25.47%	Perf Year	108.70%
Cash/sh	0.86	P/FCF	-	EPS past 3/5Y	24.13% 17.67%	ROIC	-156.86%	52W Low	0.51 375.06%	Perf 3Y	23.08%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	107.42% 8.59%	Gross Margin	-	Volatility	3.90% 5.64%	Perf 5Y	-84.19%
Dividend TTM	-	EV/Sales	3.07	EPS Y/Y TTM	-1076.54%	Oper. Margin	-192.13%	ATR (14)	0.13	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	3.83	Sales Y/Y TTM	-67.38%	Profit Margin	-149.52%	RSI (14)	52.25	Recom	3.00
Dividend Gr. 3/5Y	- -	Current Ratio	3.83	EPS Q/Q	58.59%	SMA20	-0.76%	Beta	1.48	Target Price	4.00
Payout	-	Debt/Eq	0.13	Sales Q/Q	-61.02%	SMA50	5.68%	Rel Volume	0.21	Prev Close	2.33
Employees	32	LT Debt/Eq	0.05	Earnings	Nov 13 AMC	SMA200	35.88%	Avg Volume	638.02K	Price	2.40
IPO	Nov 02, 2017	Option/Short	Yes / Yes	EPS/Sales Surpr.	48.00% -	Trades		Volume	136,577	Change	3.00%

Date	Action	Analyst	Rating Change	Price Target Change
Dec-20-24	Downgrade	Evercore ISI	Outperform → In-line	$5
Sep-23-22	Upgrade	Evercore ISI	In-line → Outperform	$2 → $8
Oct-01-21	Downgrade	Oppenheimer	Outperform → Perform
Jan-22-21	Reiterated	H.C. Wainwright	Buy	$33 → $40
Dec-16-20	Initiated	Berenberg	Buy	$47
Sep-29-20	Initiated	Evercore ISI	Outperform
Nov-05-19	Reiterated	H.C. Wainwright	Buy	$28 → $35
Sep-09-19	Initiated	Janney	Buy
Feb-09-18	Initiated	Cantor Fitzgerald	Overweight	$27
Nov-27-17	Initiated	Stifel	Buy	$26
Nov-27-17	Initiated	Oppenheimer	Outperform	$30
Nov-27-17	Initiated	BofA/Merrill	Neutral	$16

Show Previous Ratings

Nov-28-25 08:00AM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Nov-13-25 04:05PM	Spero Therapeutics Announces Third Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire) -8.27%
Nov-04-25 04:05PM	Spero Therapeutics to Report Third Quarter 2025 Financial Results and Provide Business Update on November 13, 2025 (GlobeNewswire)
Oct-21-25 02:00AM	PIVOT-PO Phase 3 Data Show Tebipenem HBr's Potential as the First Oral Carbapenem Antibiotic for Patients with Complicated Urinary Tract Infections (cUTIs) (GlobeNewswire)
Oct-14-25 08:00AM	Spero Therapeutics Announces Presentations on Tebipenem Hbr at IDWeek (GlobeNewswire)
10:00AM	Loading…
Oct-10-25 10:00AM	Best Momentum Stock to Buy for October 10th (Zacks)
Oct-08-25 11:23AM	Bayer Reports Positive Data on Cell Therapy for Parkinson's Disease (Zacks) +5.56%
Aug-19-25 09:35AM	Down 17.7% in 4 Weeks, Here's Why Spero Therapeutics (SPRO) Looks Ripe for a Turnaround (Zacks)
Aug-13-25 03:11AM	Spero Therapeutics Inc (SPRO) Q2 2025 Earnings Call Highlights: Tepipenem HBR Trial Success and ... (GuruFocus.com) -18.01%
Aug-12-25 04:01PM	Spero Therapeutics Announces Second Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire) +7.27%
Aug-05-25 04:05PM	Spero Therapeutics to Report Second Quarter 2025 Financial Results and Provide Business Update on Tuesday, August 12, 2025 (GlobeNewswire) -6.19% +6.60%
Jul-08-25 10:31AM	Bayer Begins Phase I/II Study on Cell Therapy for Eye Disease (Zacks)
Jul-04-25 08:35AM	AZN's Imfinzi Wins EU Nod for Muscle-Invasive Bladder Cancer (Zacks)
Jul-02-25 08:34AM	Vertex Gets EU Nod for New Cystic Fibrosis Drug Alyftrek (Zacks)
Jul-01-25 11:55AM	RCKT's IND for RP-A701 in Dilated Cardiomyopathy Gets FDA Clearance (Zacks)
10:05AM	Loading…
10:05AM	ABBV to Boost Immunology Pipeline With Capstan Buyout for $2.1B (Zacks)
Jun-30-25 10:40AM	Vor Bio Stock Skyrockets 250% in the Past Week: Here's Why (Zacks)
May-29-25 01:15PM	Spero Therapeutics Jumps as Oral Carbapenem Hits Phase 3 Milestone (Insider Monkey) -9.36%
11:18AM	SPRO Stock Soars 245% on GSK-Partnered UTI Drug Meeting Study Goal (Zacks)
May-28-25 07:00AM	GSK-licensed antibiotic meets goal in late-stage study (BioPharma Dive) +244.57%
07:00AM	Spero Therapeutics and GSK Announce PIVOT-PO Phase 3 Study for Tebipenem HBr Stopped Early for Efficacy Following Review by Independent Data Monitoring Committee (GlobeNewswire)
May-13-25 05:10PM	Spero Therapeutics, Inc. (SPRO) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +13.11% -5.78%
04:01PM	Spero Therapeutics Announces First Quarter 2025 Operating Results and Provides a Business Update (GlobeNewswire)
May-12-25 09:53AM	Spero Therapeutics Inc (SPRO) Q1 2025: Everything You Need To Know Ahead Of Earnings (GuruFocus.com)
May-09-25 08:20AM	UniQure (QURE) Reports Q1 Loss, Misses Revenue Estimates (Zacks) +7.83%
May-08-25 05:55PM	Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
May-07-25 05:25PM	Mirum Pharmaceuticals, Inc. (MIRM) Reports Q1 Loss, Tops Revenue Estimates (Zacks)
May-05-25 08:00AM	Spero Therapeutics to Report First Quarter 2025 Financial Results and Provide Business Update on Tuesday, May 13, 2025 (GlobeNewswire) -5.72%
Apr-28-25 04:01PM	Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer (GlobeNewswire) -5.49%
Mar-28-25 07:10AM	Q4 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -10.88%
03:03AM	Loading…
03:03AM	Spero Therapeutics Inc (SPRO) Q4 2024 Earnings Call Highlights: Navigating Financial Challenges ... (GuruFocus.com)
Mar-27-25 08:31PM	Spero Therapeutics, Inc. (SPRO) Q4 2024 Earnings Call Transcript (Seeking Alpha)
05:20PM	Spero Therapeutics, Inc. (SPRO) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-18-25 08:00AM	Spero Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Business Update on Thursday, March 27, 2025 (GlobeNewswire)
Feb-25-25 10:15AM	UPDATE Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
07:00AM	Spero Therapeutics to Present at TD Cowen 45th Annual Health Care Conference (GlobeNewswire)
Jan-15-25 12:00PM	Spero Therapeutics (SPRO) Upgraded to Buy: Here's What You Should Know (Zacks) -7.90%
Jan-10-25 07:00AM	Spero Therapeutics Provides Business Update and Announces Interim Leadership Changes (GlobeNewswire)
Dec-16-24 06:34PM	Spero Therapeutics (SPRO) Loses -9.32% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner (Zacks)
Nov-18-24 12:09PM	TenNors Phase III antibiotic trial meets all primary endpoints (Clinical Trials Arena)
Nov-14-24 05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q3 Loss, Lags Revenue Estimates (Zacks) -5.60%
04:05PM	Spero Therapeutics Announces Third Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Nov-13-24 07:29AM	What To Expect From Spero Therapeutics Inc (SPRO) Q3 2024 Earnings (GuruFocus.com)
Nov-07-24 04:05PM	Spero Therapeutics to Report Third Quarter 2024 Financial Results and Provide Business Update on Thursday, November 14, 2024 (GlobeNewswire)
Oct-30-24 08:45AM	Speros stock slides after antibiotic flops in Phase II trial (Pharmaceutical Technology)
Oct-29-24 04:05PM	Spero Therapeutics Announces SPR720 Phase 2a Interim Results and Provides a Business Update (GlobeNewswire)
Oct-16-24 04:05PM	Spero Therapeutics Announces Presentation of SPR719 (Active Moiety of SPR720) In Vitro Data Demonstrating Low Propensity for the Development of Resistance at IDWeek 2024 (GlobeNewswire)
Oct-02-24 04:30PM	Spero Therapeutics Announces Publication of SPR720 Phase 1 Lung Exposure Data in Antimicrobial Agents and Chemotherapy (GlobeNewswire)
Sep-04-24 04:05PM	Spero Therapeutics to Present at Upcoming September Investor Conferences (GlobeNewswire)
Aug-06-24 07:51AM	Q2 2024 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents) -5.22%
Aug-05-24 08:59PM	SPRO Stock Earnings: Spero Therapeutics Beats EPS, Beats Revenue for Q2 2024 (InvestorPlace)
05:35PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Second Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
Jul-29-24 04:05PM	Spero Therapeutics to Report Second Quarter 2024 Financial Results and Provide Business Update on Monday, August 5, 2024 (GlobeNewswire)
Jul-08-24 03:07PM	3 Micro-Cap Moonshots for Fearless Investors (InvestorPlace)
Jul-03-24 01:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-03-24 04:05PM	Spero Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-16-24 04:05PM	Spero Therapeutics to Participate in H.C. Wainwright Annual BioConnect Investor Conference (GlobeNewswire)
May-15-24 08:55PM	SPRO Stock Earnings: Spero Therapeutics Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace)
04:05PM	Spero Therapeutics Announces First Quarter 2024 Operating Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:00AM	Spero Therapeutics to Report First Quarter 2024 Financial Results and Provide Business Update on Wednesday, May 15, 2024 (GlobeNewswire)
May-01-24 04:07PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +8.80%
Apr-16-24 11:52AM	14 Cheap Penny Stocks to Buy According to Analysts (Insider Monkey)
Mar-15-24 12:51PM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q4 2023 Earnings Call Transcript (Insider Monkey)
Mar-14-24 06:33AM	Q4 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Mar-13-24 05:10PM	Spero Therapeutics, Inc. (SPRO) Q4 Earnings and Revenues Top Estimates (Zacks)
04:01PM	Spero Therapeutics Announces Fourth Quarter and Full Year 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Mar-06-24 08:05AM	Spero Therapeutics to Provide Business Update and Report Fourth Quarter and Full Year 2023 Financial Results on Wednesday, March 13, 2024 (GlobeNewswire)
Feb-28-24 08:05AM	Spero Therapeutics Announces Clearance of IND for SPR206 to Treat MDR Gram-negative Bacterial Infections (GlobeNewswire)
Feb-26-24 08:05AM	Spero Therapeutics to Present at Cowen's 44th Annual Healthcare Conference (GlobeNewswire)
Feb-05-24 11:27PM	Spero Therapeutics Inc CEO Sath Shukla Sells 75,994 Shares (GuruFocus.com)
Jan-31-24 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jan-29-24 04:07AM	15 Cash-Rich Penny Stocks Hedge Funds Are Buying (Insider Monkey)
Jan-25-24 04:40AM	11 Hyper-Growth Stocks Billionaires Are Loading Up On (Insider Monkey)
Jan-05-24 08:05AM	Spero Therapeutics Provides Corporate Update and 2024 Outlook (GlobeNewswire)
Jan-02-24 08:05AM	Spero Therapeutics Announces First Patient, First Visit for Phase 3 PIVOT-PO Trial Evaluating Tebipenem HBr in Complicated Urinary Tract Infections (GlobeNewswire)
Nov-14-23 09:02AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-13-23 04:05PM	Spero Therapeutics Announces Third Quarter 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Nov-06-23 08:05AM	Spero Therapeutics to Provide Business Update and Report Third Quarter 2023 Financial Results on Monday, November 13, 2023 (GlobeNewswire)
Nov-01-23 04:05PM	Spero Therapeutics to Present at Upcoming November Investor Conferences (GlobeNewswire) +5.56%
08:05AM	Spero Therapeutics Appoints Esther Rajavelu as Chief Financial Officer and Chief Business Officer (GlobeNewswire)
Oct-31-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-18-23 12:00PM	All You Need to Know About Spero Therapeutics, Inc. (SPRO) Rating Upgrade to Buy (Zacks)
Sep-29-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-20-23 04:05PM	Spero Therapeutics to Present at Cantors Global Healthcare 2023 Investor Conference (GlobeNewswire)
Sep-16-23 01:01PM	Insider Sell: Chief Medical Officer Kamal Hamed Sells 39,496 Shares of Spero Therapeutics Inc (GuruFocus.com)
Sep-12-23 08:00AM	Sensorium Therapeutics Appoints Veteran Life Sciences Executive Mr. David Southwell to its Board of Directors (GlobeNewswire)
Sep-06-23 08:05AM	Spero Therapeutics to Present at H.C. Wainwright 25th Annual Global Investment Conference (GlobeNewswire)
Aug-31-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-29-23 12:00PM	Spero Therapeutics, Inc. (SPRO) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks) +8.73%
Aug-22-23 05:45PM	Down -11.72% in 4 Weeks, Here's Why Spero Therapeutics, Inc. (SPRO) Looks Ripe for a Turnaround (Zacks)
Aug-13-23 05:24AM	Spero Therapeutics, Inc. (NASDAQ:SPRO) Q2 2023 Earnings Call Transcript (Insider Monkey)
Aug-11-23 06:32AM	Q2 2023 Spero Therapeutics Inc Earnings Call (Thomson Reuters StreetEvents)
Aug-10-23 06:05PM	Spero Therapeutics, Inc. (SPRO) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Spero Therapeutics Announces Second Quarter 2023 Operating Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 08:05AM	Spero Therapeutics to Provide Business Update and Report Second Quarter 2023 Financial Results on Thursday, August 10, 2023 (GlobeNewswire)
Jul-31-23 08:05AM	Spero Therapeutics Announces Special Protocol Assessment Agreement with FDA for Phase 3 PIVOT-PO Trial of Tebipenem HBr (GlobeNewswire) +14.79%
Jul-05-23 06:20AM	Investors in Spero Therapeutics (NASDAQ:SPRO) have unfortunately lost 90% over the last three years (Simply Wall St.)
Jun-30-23 04:05PM	Spero Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)

Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Rajavelu Esther	See Remarks	Nov 07 '25	Sale	2.37	40,270	95,440	869,450	Nov 12 08:44 PM
Mahadevia Ankit	Director	Aug 28 '25	Sale	1.97	6,572	12,947	703,294	Sep 03 06:04 AM
Keutzer Timothy	Chief Operating Officer	Aug 28 '25	Sale	1.97	1,695	3,339	739,744	Sep 03 06:02 AM
Keutzer Timothy	Chief Operating Officer	Feb 05 '25	Sale	0.78	56,537	44,099	741,439	Feb 05 09:04 PM
Rajavelu Esther	CFO & CBO	Feb 05 '25	Sale	0.78	20,689	16,137	724,720	Feb 05 08:52 PM
Shukla Sath	CEO & President	Feb 05 '25	Sale	0.78	155,333	121,160	1,736,883	Feb 05 08:31 PM
Mahadevia Ankit	Director	Feb 05 '25	Sale	0.78	69,219	53,991	689,866	Feb 05 08:30 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Black Swan Sale

50% Off Elite

SPRO

Spero Therapeutics Inc

Upgrade your FINVIZ experience